Recursion Pharmaceuticals Inc vs Wendys Co — how do they compare? Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B), while Wendys Co trades at $7.62 (market cap $1.50B). The key difference: Recursion Pharmaceuticals Inc and Wendys Co are close in size by market cap, and Wendys Co pays a 7.13% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | WEN | |
|---|---|---|
Market Cap | $1.53B | $1.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $11.33 |
52-Week Low | $2.84 | $6.17 |
Enterprise Value | $946.50M | $5.31B |
Dividend Yield | — | 7.13% |
Trailing returns across standard periods
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →